Immunosuppressants - Qatar

Qatar

The Immunosuppressants market in Qatar is expected to witness a significant increase in revenue, reaching US$15.56m in 2024.
Moreover, the market is projected to display a steady annual growth rate (CAGR 2024-2029) of 15.71%, leading to a market volume of US$32.27m by 2029.
When compared globally, United States is anticipated to generate the highest revenue in this market, with a staggering US$35,470.00m in 2024.
Qatar's immunosuppressant market is experiencing a surge in demand due to the country's growing population of transplant recipients.

Key regions: Australia, Germany, United Kingdom, United States, France

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for immunosuppressants in Qatar has been on the rise in recent years.

Customer preferences: Patients in Qatar suffering from autoimmune diseases such as rheumatoid arthritis, lupus, and psoriasis have been the primary consumers of immunosuppressants. Additionally, individuals who have undergone organ transplants also require immunosuppressants to prevent their bodies from rejecting the new organs.

Trends in the market: The immunosuppressants market in Qatar has been growing due to the increasing prevalence of autoimmune diseases and organ transplant surgeries. The market has also been driven by the availability of advanced immunosuppressant drugs that have fewer side effects and are more effective in treating these diseases. The government's efforts to improve healthcare facilities, including the expansion of hospitals and clinics, have also contributed to the growth of the market.

Local special circumstances: Qatar is a wealthy country with a high standard of living, and its citizens have access to quality healthcare. The country has a universal healthcare system that provides free or subsidized healthcare to its citizens. Additionally, Qatar is a hub for medical tourism, attracting patients from neighboring countries who require specialized medical treatment.

Underlying macroeconomic factors: Qatar's economy is heavily dependent on its oil and gas industry, which accounts for more than 50% of its GDP. The country has been investing heavily in infrastructure development, including healthcare facilities, to diversify its economy and reduce its reliance on oil and gas. The government's efforts to improve healthcare facilities have contributed to the growth of the immunosuppressants market in Qatar.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.